US4448779A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of MS salt in geriatric medicine
Assignee: Sanofi Aventis France
•
Filing: 1981-07-16
•
Granted: 1984-05-15
•
Expires: 2001-07-16
Abstract
Abstract Administration of the known drug 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate ("MS salt" or "PCR") is described for the alleviation of the symptoms of senility such as of organic brain syndrome and senile dementia.
Inventors
- 👤 Jean F. Blanchard
- 👤 Pierre P. Lasserre
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 13:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
42 words
A geriatric method which comprises administering orally to an aged person a composition which comprises a biologically acceptable carrier and as the active ingredient, 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate, in an effective amount, and alleviating symptoms of organic brain syndrome of that person.
Claim 2
Dependent Claim
42 words
A geriatric method which comprises administering orally to an aged person a composition which comprises a biologically acceptable carrier and as the active ingredient, 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate, in an effective amount, and alleviating symptoms of organic brain syndrome of that person.
Claim 3
Dependent Claim
29 words
The method of claim 1 in which the symptoms which are alleviated are the symptoms of senile deterioration in the symptom areas of the modified Sandoz Clinical Assessment-Geriatric Evaluation.
Claim 4
Dependent Claim
17 words
The method of claim 1 in which the symptoms which are alleviated include impairment of recent memory.
Claim 5
Dependent Claim
17 words
The method of claim 1 in which the symptom which is alleviated is lack of mental alertness.
Claim 6
Dependent Claim
15 words
The method of claim 1 in which the symptom which is alleviated is mood depression.
Claim 7
Dependent Claim
15 words
The method of claim 1 in which the symptom which is alleviated is emotional lability.
Claim 8
Dependent Claim
14 words
The method of claim 1 in which the symptom which is alleviated is disorientation.
Claim 9
Dependent Claim
14 words
The method of claim 1 in which the symptom which is alleviated is fatigue.
Claim 10
Dependent Claim
28 words
The method of claim 1 in which the symptoms which are alleviated include the following: mental alertness, impairment of recent memory, mood depression, emotional lability, disorientation and fatigue.
Claim 11
Dependent Claim
13 words
The method of claim 1 wherein the daily dosage is about 500 mg.
Claim 12
Dependent Claim
15 words
The method of claim 1 wherein the composition is administered for at least 1 month.
Claim 13
Dependent Claim
15 words
The method of claim 1 wherein the composition is administered for at least 2 months.
Claim 14
Dependent Claim
34 words
A composition for use in geriatric therapy which comprises a pharmaceutically acceptable carrier and, in an effective amount to alleviate the symptoms of organic brain syndrome, 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate as the active ingredient.
Claim 15
Dependent Claim
34 words
A composition for use in geriatric therapy which comprises a pharmaceutically acceptable carrier and, in an effective amount to alleviate the symptoms of organic brain syndrome, 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate as the active ingredient.
Claim 16
Dependent Claim
43 words
A composition for use in geriatric therapy especially suited for oral administration which comprises a pharmaceutically acceptable carrier and, in an effective amount to alleviate at least one of the symptoms of organic brain syndrome, 5-o-cyanobenzyl-4,5,6,7,-tetrahydrothieno [3,2-c] pyridine methanesulfonate as the active ingredient.
Claim 17
Dependent Claim
43 words
A composition for use in geriatric therapy especially suited for oral administration which comprises a pharmaceutically acceptable carrier and, in an effective amount to alleviate at least one of the symptoms of organic brain syndrome, 5-o-cyanobenzyl-4,5,6,7,-tetrahydrothieno [3,2-c] pyridine methanesulfonate as the active ingredient.
Claim 18
Dependent Claim
66 words
A geriatric method which comprises administering to an aged person having the symptoms which include at least one of the following: mental alertness, impairment of recent memory, mood depression, emotional liability, disorientation and fatigue, a composition comprising a pharmaceutically acceptable carrier and as the active ingredient, an effective amount of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate so as to cause alleviation of at least one of said symptoms.
Claim 19
Dependent Claim
66 words
A geriatric method which comprises administering to an aged person having the symptoms which include at least one of the following: mental alertness, impairment of recent memory, mood depression, emotional liability, disorientation and fatigue, a composition comprising a pharmaceutically acceptable carrier and as the active ingredient, an effective amount of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate so as to cause alleviation of at least one of said symptoms.
Claim 20
Dependent Claim
53 words
A geriatric method which comprises orally administering to an aged person a composition comprising a pharmaceutically acceptable carrier and 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methansulfonate in an effective amount to inhibit at least one of the symptoms of organic brain syndrome including mental alertness, impairment of recent memory, mood depression, emotional lability, disorientation and fatigue.
Claim 21
Dependent Claim
53 words
A geriatric method which comprises orally administering to an aged person a composition comprising a pharmaceutically acceptable carrier and 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methansulfonate in an effective amount to inhibit at least one of the symptoms of organic brain syndrome including mental alertness, impairment of recent memory, mood depression, emotional lability, disorientation and fatigue.
References Cited (Backward Citations)
US4097482A
Cited
US4147787A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-15 | 1987-11-14 | 1988-05-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-15 | 1991-11-14 | 1992-05-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-15 | 1995-11-14 | 1996-05-15 | $7700.00 | Window Closed / Lapsed |